Sofinnova Ventures

Since 1974, Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build successful teams, win key customers, and navigate acquisitions and IPOs. Sofinnova Ventures invests in Life Science and Technology start-ups. Their professionals are seasoned business operators, possessing deep domain and investment expertise. They know how to help entrepreneurs build successful, global businesses.

Nathalie Auber

Partner and CFO

Alain Azan

Founding Partner

Sarah Bhagat

General Partner

Chris Carpenter

Executive Partner

Alan Colowick

Partner

Eric Delbridge

Portfolio Manager and Partner, Public Equity

Lars Ekman

Executive Partner, Private Equity

James I. Healy

Managing Partner

Noel Jee

Principal, Private Equity

David Kabakoff

Executive Partner, Private Equity

Maha Katabi

General Partner

Jonathan Leff

Executive Partner, Private Equity

Anand Mehra

General Partner

Perry D. Nisen

Executive Partner, Private Equity

Pitt, Cameron L.W.

Principal of Private Equity

Jason Pitts

Principal of Private Equity

Regina Salvat

Principal, Private Equity

Hooman Shahlavi

Partner and Chief Legal Officer

Charlotte Shropshire

Director of Investor Relations and Marketing

Goro Takeda

Venture Partner

Daniel G. Welch

Executive Partner, Private Equity

Alfred Yue

VP Finance

318 past transactions

Wyplay

Series B in 2008
WYplay SAS develops digital TV software solutions. The company provides television and home media connected platforms for markets in North America. It offers software licensing to turnkey products, media center consumer electronic (CE) devices, full-HD IPTV boxes, DVB set top boxes, connected televisions, and in-home HD multimedia-HDD products. The company also offers media management, home networking, and connectivity products, as well as connected digital media player, digital media server, CD/DVD optical drive, browser, and analog acquisition components. WYplay SAS was founded in 2006 and is based in Allauch, France.

DiObex

Series B in 2007
DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.

Natera

Venture Round in 2014
Natera is driven by a passion for elevating the science and utility of prenatal testing. The advent of the Information Age has created a paradigm shift in the fields of computing and informatics. Surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing.

Amplyx Pharmaceuticals, Inc.

Private Placement in 2017
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

NorthSea Therapeutics

Venture Round in 2019
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

Iterum Therapeutics plc

Series A in 2016
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Intrinsa

Venture Round in 2002
Intransa, Inc. provides products for video security projects. It offers VideoAppliance, which delivers ready out-of-the-box appliances that slash the installation and integration process; EnterpriseServer that delivers installer-ready servers that are tuned and optimized for demands of physical security with Microsoft Server 2008; EnterpriseStorage, which reduces the risk of lost video data; and ViewingStation for remote viewing of multiple high definition streams for video surveillance applications. It serves retail and banking, public safety, manufacturing, transportation, schools and education, gaming and hospitality, government, and health care sectors. The company offers its products through distributors. Intransa, Inc. was founded in 2001 and is headquartered in Menlo Park, California.
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Saegis Pharmaceuticals

Series B in 2003
Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma. Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.

PregLem

Series B in 2007
PregLem is a Swiss based specialty biopharmaceutical company dedicated to the development and commercialisation of innovative drugs for women's reproductive medicine.

Vicept Therapeutics

Series A in 2010
Vicept (Vicept Therapeutics, Inc.), based in Malvern, Pennsylvania, is a privately held specialty biopharmaceutical company founded in August, 2009 with a mission to develop the first effective topically applied-therapy directed toward the erythema (skin redness) of rosacea and other dermatologic disorders characterized by redness and or 'flushing' of the skin.

Galera Therapeutics, Inc.

Series C in 2018
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company’s lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer. It is also involved in developing GC4711, which is in Phase I/II clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.

Intellikine

Series B in 2007
Intellikine works in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway. Intellikine is committed to building an exceptional team and a powerful discovery platform that rapidly generates small molecule kinase inhibitor drug candidates that will become the next generation of medical breakthroughs.

Cotherix

Series C in 2003
Cotherix is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. Ventavis, our lead product candidate, is an inhaled formulation of iloprost.

OpenReach

Venture Round in 2004
OpenReach is a provider of virtual private networking (VPN) software and services.

Lysogene S.A.

Series A in 2014
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders . Their mission is to radically improve the health of patients suffering from incurable life threatening conditions. They do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.

Rainier Therapeutics

Series B in 2018
Rainier Therapeutics, Inc., a biotechnology company, develops a targeted biologic for the potential treatment of early stage and metastatic bladder cancer. It offers Vofatamab (B-701), a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) that is used for the treatment for metastatic bladder cancer. Rainier Therapeutics, Inc. was formerly known as BioClin Therapeutics, Inc. and changed its name to Rainier Therapeutics, Inc. in November 2018. The company was founded in 2010 and is based in San Leandro, California.

PhyFlex Networks

Venture Round in 2004
PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Guavus

Series B in 2011
Guavus solves the world’s most complex data problems. Proven across Fortune 500 enterprises, Guavus provides a new generation of analytically powered big data applications to address specific business problems for next-generation service assurance, next-generation customer experience management and the Internet of Things. The Company uniquely breaks down the barriers between Operational Support Systems and Business Support Systems to enable customers to more efficiently plan network capacity, improve service operations and deliver a better customer experience. Guavus’ operational intelligence applications correlate and analyze massive amounts of streaming and stored business, operational and sensor data from multiple, disparate source systems in real time. Guavus products currently process more than two Trillion transactions per day.

Entelos

Venture Round in 1999
Entelos is the leading provider of predictive biosimulation for drug discovery and development. We provide advanced biosimulation capabilities that make discovery more efficient and increase clinical success. For over 15 years, we have enabled R&D organizations to predict better paths to success by simulating systems biology. Our solutions include mechanism-based, mathematical models; virtual patients and populations; biosimulation software; and biosimulation expertise.

Ascendis Pharma

Series D in 2014
Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugs of proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.

NorthSea Therapeutics

Series C in 2021
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

Antiva Biosciences, Inc.

Series D in 2021
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Vicept Therapeutics

Venture Round in 2009
Vicept (Vicept Therapeutics, Inc.), based in Malvern, Pennsylvania, is a privately held specialty biopharmaceutical company founded in August, 2009 with a mission to develop the first effective topically applied-therapy directed toward the erythema (skin redness) of rosacea and other dermatologic disorders characterized by redness and or 'flushing' of the skin.

Trius Therapeutics

Series A in 2007
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. We have successfully completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections. Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory experience. Our senior management team consists of nine individuals who collectively have been involved in the development and approval of a significant number of anti-infective drugs.

Prestwick Pharmaceuticals

Series B in 2004
Prestwick Pharmaceuticals develops and markets therapeutic pharmaceutical drugs for chronic central nervous systems diseases. The company offers products for restless legs syndrome, schizophrenia, autism, Alzheimer’s, and sleep apnea ailments. Prestwick Pharmaceuticals was founded in 2002 and is based in Washington, District of Columbia.

Seres Health

Venture Round in 2004
Seres Health is a clinical-stage therapeutics company focused on discovering and developing drugs to treat diseases of the microbiome. The biology of the microbiome is driven by ecologies—the functional collections of various organisms—which are central to health and disease. Seres is developing Ecobiotic™ therapeutics to treat diseases that have an underlying microbiome biology. Our first clinical program is in the treatment of Clostridium difficile infection.

ConteXtream

Series A in 2007
ConteXtream is a privately held software company delivering the industry’s first cloud-based network virtualization framework that enables network operators to leverage the power of proven virtualization and grid technologies to extract more value and profitability from their broadband networks. The ConteXtream Service Delivery Grid delivers higher network performance at a lower cost per subscriber while enabling operators to customize applications on a per-session, per- subscriber basis for a unique, highly personalized subscriber experience. Headquartered in Santa Clara, Calif., ConteXtream is backed by leading Silicon Valley and global investors including Benhamou Global Ventures, Gemini Israel Funds, Norwest Venture Partners and Sofinnova Ventures as well as Comcast Interactive Capital and Verizon Investments.

Quanta Therapeutics

Series C in 2021
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.

Merus

Post in 2018
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.

NextCure

Series B in 2018
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.
Hyperion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat orphan diseases in the United states, Canada, and internationally. The company offers RAVICTI used as a nitrogen-binding agent for chronic management of urea cycle disorder (UCD) in adult and pediatric patients; and BUPHENYL and AMMONAPS therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate, an active pharmaceutical ingredient in RAVICTI to treat hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California. As of May 7, 2015, Hyperion Therapeutics, Inc. operates as a subsidiary of Horizon Pharma USA, Inc.

Y-mAbs Therapeutics

Private Equity Round in 2017
YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval.
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.

Humanigen, Inc.

Series B in 2005
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.
Hyperion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat orphan diseases in the United states, Canada, and internationally. The company offers RAVICTI used as a nitrogen-binding agent for chronic management of urea cycle disorder (UCD) in adult and pediatric patients; and BUPHENYL and AMMONAPS therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate, an active pharmaceutical ingredient in RAVICTI to treat hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California. As of May 7, 2015, Hyperion Therapeutics, Inc. operates as a subsidiary of Horizon Pharma USA, Inc.

RayzeBio

Series D in 2022
RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

Threshold Pharmaceuticals

Series B in 2004
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.

Humanigen, Inc.

Seed Round in 2003
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Anza Therapeutics

Venture Round in 2007
Anza Therapeutics is a biotechnology company that develops immunotherapies for infectious diseases and cancer. The company's agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease.

Quanta Therapeutics

Venture Round in 2018
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.

Calient Technologies

Series D in 2004
Calient provides high-density 3D MEMS (Micro-Electro-Mechanical Systems) optical circuit switching for software-defined networks and data centers. Its optical circuit switching technology is used by service providers, cloud computing, content delivery, and government networks. This offers businesses with adaptive photonic switching systems that enable dynamic optical layer optimization in software-defined networks and data centers. The company’s 3D-MEMS switches enable dynamic optical-layer sharing, optimization, and automation of high-performance test, compute, and network resources in data centers, optical transport networks, and DevOps test automation facilities. Calient Technologies was established in 1999 and is headquartered in Goleta, California.

InteKrin

Series B in 2007
InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.

Aclaris Therapeutics

Venture Round in 2009
Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.

SARcode Bioscience

Series B in 2011
SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the treatment of significant unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.

ENOVIX

Series C in 2012
Enovix develops 3D wave array energy storage architecture for Lithium-based cells, to improve the manageability of the stored energy. The company's systems combine innovative 3D cell architecture with an innovative business model to build a better battery business and meet the increasing energy needs of mobile devices, enabling companies to increase energy density and eliminates thermal runaway of their battery-operated products. It was founded in 2006 and headquartered in Fremont, California.

CellZome

Series B in 2001
CellZome is a pharmaceutical company that discovers, develops, and commercializes kinase-targeted drugs for the treatment of inflammatory diseases. It develops a pipeline of kinase inhibitors targeting inflammatory mediators as oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma. CellZome was founded in 2000 and is based in Heidelberg, Baden-Wurttemberg.

Invitae

Series F in 2014
Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. What’s our plan? It takes three steps: --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine. Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

NextWave Pharmaceuticals

Series A in 2005
NextWave Pharmaceuticals, a Cupertino, CA-based pharmaceutical company that develops and commercializes products utilizing proprietary drug delivery technology.

Calient Technologies

Venture Round in 2006
Calient provides high-density 3D MEMS (Micro-Electro-Mechanical Systems) optical circuit switching for software-defined networks and data centers. Its optical circuit switching technology is used by service providers, cloud computing, content delivery, and government networks. This offers businesses with adaptive photonic switching systems that enable dynamic optical layer optimization in software-defined networks and data centers. The company’s 3D-MEMS switches enable dynamic optical-layer sharing, optimization, and automation of high-performance test, compute, and network resources in data centers, optical transport networks, and DevOps test automation facilities. Calient Technologies was established in 1999 and is headquartered in Goleta, California.

XyloCor Therapeutics, Inc.

Venture Round in 2021
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patients with refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.

Movetis

Series A in 2007
Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

Phenomix

Series B in 2005
As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

Prestwick Pharmaceuticals

Venture Round in 2002
Prestwick Pharmaceuticals develops and markets therapeutic pharmaceutical drugs for chronic central nervous systems diseases. The company offers products for restless legs syndrome, schizophrenia, autism, Alzheimer’s, and sleep apnea ailments. Prestwick Pharmaceuticals was founded in 2002 and is based in Washington, District of Columbia.

MXP4

Series C in 2010
MXP4 develops interactive music solutions that create revenue opportunities for the music, media and marketing industries. Creating a video game-like environment where consumers can play with the music, MXP4-powered applications are proven to drive engagement, viral distribution and music purchases. The MXP4 Everywhere roadmap ensures the interactive music technology is readily available in third party services, apps and music formats for implementation by brands, advertisers, media portals, mobile applications, music distribution platforms and third-party music formats. When a fan sees the MXP4 logo on a music app, it means they can play with the music. MXP4 is led by a team of music industry and digital media experts, including former senior executives of Musiwave, Vivendi Mobile Entertainment, EMI Music and DivX. The company is backed by Orkos Capital, Sofinnova Partners and Ventech.

Auris Medical

Series C in 2013
They at Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus and restore balance. Auris Medical is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo. They have additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.

Kiniksa Pharmaceuticals, Ltd.

Private Placement in 2018
Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with a significant unmet medical need. It has a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. It has three clinical-stage product candidates, one of which is anticipated to commence a Phase 3 clinical trial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action. The company's portfolio of product candidates offers multiple development opportunities. By modulating different parts of the innate and adaptive immune system, these product candidates together have the potential to provide a variety of mechanisms to address multiple devastating diseases.

Iterum Therapeutics plc

Private Placement in 2017
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

KXEN

Series D in 2010
KXEN, Inc., a data mining automation company, provides business analytics software in the areas of customer lifecycle analytics, supply chain analytics, and business intelligence for corporate business decisions. It offers various software packages that cover various functions and data manipulations options, including classification, regression, clustering, variable importance, segmentation, times series, association rules, and data fusion. The company also provides single-purpose analysis applications for forecasting, market basket analysis, prediction, and segmentation, as well as KXEN Analytic Framework, which comprises of components that are used together with modeling assistant and robust reporting as a data mining automation solution. In addition, it offers technical support services, including assistance in the initial setup of new installations and problems that arise during the use of products; education services, such as training courses and certification programs; and consulting services. The company serves its clients primarily in financial services, telecommunications, and retail industries. It offers its products through systems integrators, software vendors, and original equipment manufacturers in the United States and internationally. KXEN, Inc. has strategic partnerships with Hewlett-Packard Company; IBM; SPSS, Inc.; Sun Microsystems, Inc.; and Teradata. The company was founded in 1998 and is based in San Francisco, California with additional offices in the United States, Canada, the United Kingdom, and France.
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patients with refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.

Ophthotech

Venture Round in 2013
Ophthotech Corporation, a biopharmaceutical company, develops various therapeutics to treat diseases of the eye. It is developing Fovista, which has completed Phase IIb clinical trials for use in combination with anti-VEGF drugs for the treatment of wet age-related macular degeneration (wet AMD); and ARC1905, a potent and selective inhibitor of complement factor C5 that has completed Phase I/IIa clinical trials to treat wet AMD. The company was founded in 2007 and is headquartered in New York, New York.
Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

Galera Therapeutics, Inc.

Private Placement in 2018
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company’s lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer. It is also involved in developing GC4711, which is in Phase I/II clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.

Anesiva

Venture Round in 2001
Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management worldwide. Its lead product candidate includes Adlea, which completed multiple Phase II and Phase III trials for post-surgical, musculoskeletal, and neuropathic pain. The company was formerly known as AlgoRx Pharmaceuticals, Inc., it changed its name to Anesiva, Inc. in 2006. Anesiva, Inc. was founded in 1999 and is headquartered in South San Francisco, California. On January 15, 2010, Anesiva, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California. On June 10, 2014 filed for Chapter 7 bankruptcy.

aTyr Pharma, Inc.

Series E in 2015
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Hyperion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat orphan diseases in the United states, Canada, and internationally. The company offers RAVICTI used as a nitrogen-binding agent for chronic management of urea cycle disorder (UCD) in adult and pediatric patients; and BUPHENYL and AMMONAPS therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate, an active pharmaceutical ingredient in RAVICTI to treat hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California. As of May 7, 2015, Hyperion Therapeutics, Inc. operates as a subsidiary of Horizon Pharma USA, Inc.
Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvine's lead product candidate, ALV003, is a combination protease engineered to digest gluten. It is being developed to treat patients with celiac disease.
Aeovian Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of age-related and other diseases. The company's therapeutics inhibit the mTORC1 and mTORC2 pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress. Aeovian Pharmaceuticals, Inc. was formerly known as Delos Pharmaceuticals, Inc. The company was founded in 2012 and is based in San Francisco, California.

Civitas Therapeutics

Series C in 2014
Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

McPhy

Venture Round in 2010
McPhy Energy S.A. develops and supplies hydrogen production, storage, and distribution equipment for hydrogen energy, zero emission mobility, and industrial hydrogen markets worldwide. The company offers alkaline electrolyzers, including small, medium, and large hydrogen production units; and hydrogen storage solutions. It also designs medium and large hydrogen stations; and integrated hydrogen solutions. The company was founded in 2008 and is based in La Motte, France.

Reef Point Systems

Venture Round in 2000
As of December 2007, Reef Point Systems, Inc. was acquired by NextPoint Networks, Inc. Reef Point Systems, Inc. provides security solutions for converged wireless and wireline networks in the United States. Its iQ product portfolio enables fixed/mobile convergence security, secure mobile access, network infrastructure protection, and managed security services. It enables operators to secure voice over the Internet protocol, Internet protocol television, and voice, video, and data services from a converged Internet protocol infrastructure. The company’s iQ family lets wireless service providers protect the wireless network infrastructure and deliver multimedia services for mobile users over unlicensed mobile access and Internet protocol multimedia subsystem infrastructure. Its products also enable service providers to offer various security services, including virtual private networks, firewalls, denial of service attack prevention, content filtering, and remote access. The company, formerly known as Quarry Technologies, Inc., was founded in 1998 and is headquartered in Burlington, Massachusetts.

Inozyme Pharma, Inc.

Private Placement in 2018
Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

InteKrin

Series C in 2008
InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity.

mNemoscience

Venture Round in 1999
mNemoscience is a privately held company designs, develops, manufactures, and commercializes biocompatible shape memory polymers. The company offers BIO-SMP-based absorbable surgical sutures; and polymer scaffolds. It also develops and commercializes its BIO-SMP technology for licensing to external partners. The company's products are used in various industries such as medical devices, automotive, electronics, textiles or packaging, and may enable the development of groundbreaking products and therapies. In 2009, the company filed for bankruptcy due to financial problems.

Athira Pharma

Private Placement in 2020
Athira Pharma, Inc., a clinical-stage biopharmaceutical company, develops small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in various clinical trials for the treatment of Alzheimer’s and Parkinson’s diseases. The company also develops product candidates, which are in preclinical stage, including ATH-1019 for depression; and ATH-1018 for peripheral neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is based in Seattle, Washington.

Checkmate Pharmaceuticals, Inc.

Private Placement in 2017
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

HeadSprout

Venture Round in 2001
HeadSprout, Inc. provides computer-based learning programs for teaching fundamental academic skills. It offers online reading programs. The company was founded in 1999 and is headquartered in Seattle, Washington.
Crocus Technology SA provides magnetic random access memory products and technologies for the semiconductor and electronic systems industries. It offers its products for use in telecommunication, networking, storage, computing, and handheld applications.
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California.

Tensys Medical

Series A in 2000
Tensys Medical, Inc. engages in the development and commercialization of continuous, non-invasive, and hemodynamic monitoring systems. The company offers TL-300, a tablet supported blood pressure monitoring system that allows touch screen control and displays a patient’s key hemodynamic parameters. Its T-Line family of products allow early recognition and treatment of rapid changes in blood pressure in the OR, and improves the diagnosis and management of cardiovascular conditions. The company’s products are used in hospital operating rooms, ICUs, and electrophysiology labs to provide a patient’s real-time pulse pressure waveform and blood pressure. Tensys Medical, Inc. was formerly known as VitalWave Corporation. The company was founded in 1995 and is based in San Diego, California.

Stentys

Series B in 2009
STENTYS S.A., a medical technology company, develops solutions for treating patients with acute myocardial infarction and other coronary disease in Europe, the Middle East, Latin and South America, and South East Asia. Its product portfolio consists of Xposition S, a sirolimus-eluting self-apposing coronary stent system; Serpentis, a sirolimus eluting stent with a bioabsorbable polymer; MiStent SES, a sirolimus eluting absorbable polymer coronary stent system; and STENTYS AC, an aspiration catheter. The company serves interventional cardiologists. STENTYS S.A. was founded in 2006 and is based in Paris, France.

Orexo

Series B in 2003
Orexo develops improved specialty pharmaceuticals and treatments for new areas of use – at a lower cost, in a shorter period of time and at a lower risk – by combining known substances with patented proprietary technologies.

NextCure

Series A in 2016
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.

First Aid Shot Therapy

Series C in 2015
First Aid Shot Therapy offers a market segment defined as clinical beverages designed to address acute or chronic clinical needs. It offers a range of easy-to-swallow, single-dose products that provide fast-acting relief for most common everyday symptoms; hangover, pain, sleep, cold, allergy, and heartburn. The company was founded in 2010 and is headquartered in Burlingame, California.

Intrepida Bio

Private Placement in 2019
Intrepida Bio, Inc., a biotechnology company, develops cancer drugs that alter the body’s first line of defense, and innate immunity. It also discovers and develops medicines that modulate the innate immune system to fight cancer and other diseases; and develops monoclonal antibodies that block the novel targets BAG3 and its receptor IFITM-2 to thwart their ability to create a favorable environment for tumor growth. Intrepida Bio, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

ObsEva

Post in 2017
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2α, or PGF2α receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Tesaro, Inc.

Series C in 2012
Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

Promedior

Private Placement in 2019
Promedior, Inc. a clinical-stage biotechnology company, develops therapeutics to treat rare fibrotic diseases, such as myelofibrosis and idiopathic pulmonary fibrosis; and retinal fibrovascular diseases, such as age related macular degeneration and diabetic retinopathy. Its portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein (rhPTX-2) formulated for intravenous injection; and PRM-167, a variant of rhPTX-2 developed for intravitreal delivery in retinal fibrovascular diseases. Promedior, Inc. was formerly known as Fibrotix, Inc. The company was incorporated in 2006 and is based in Lexington, Massachusetts. As of February 13, 2020, Promedior, Inc. operates as a subsidiary of Roche Holding AG.

Cortina Systems

Series D in 2006
Cortina Systems is a leading supplier of intelligent communication solutions through continuous innovations in advanced port processing and connectivity to the Core, Metro, Access, and Enterprise Market Segments. With our state-of-the-art high-speed analogdigital integration, we deliver a wide suite of products that address our customers' performance, density, and flexibility needs enabling faster time-to-market, longer time-in-market, and increased revenue opportunities. Working closely with our customers to understand their system requirements and anticipate their needs, we are creating the foundation ingredients for new generations of services.

Vera Therapeutics, Inc.

Private Placement in 2020
Vera Therapeutics, Inc., a biotechnology company, develops biologic therapeutics. Vera Therapeutics, Inc. was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in March 2020. The company was founded in 2016 and is based in South San Francisco, California.

CinCor Pharma

Series A in 2019
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, develops clinical candidates for cardiovascular, metabolic, and kidney diseases. It focuses on developing CIN-107, a aldosterone synthase inhibitor for the treatment of resistant hypertension and primary aldosteronism. The company was founded in 2018 and is based in Cincinnati, Ohio.

Trucode Gene Repair, Inc.

Series C in 2021
Trucode Gene Repair, Inc. operates a triplex gene editing platform for curing genetic diseases. It focuses on sickle cell disease and cystic fibrosis. The company develops a pipeline of novel, proprietary therapeutic products for high-penetrance disease genes to alleviate and cure genetic disorders in patients. The company was founded in 2016 and is based in South San Francisco, California.
Neurana Pharmaceuticals, Inc. is a pharmaceutical company that develops treatment for neuromuscular conditions, including acute and painful muscle spasms of the neck and back. The company provides Tolperisone, a therapeutic compound that treats musculoskeletal conditions, including neuromuscular spasms and spasticity without sedation. The company was formerly known as Katama Pharmaceuticals Inc. Neurana Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in San Diego, California.

AFYX Therapeutics A/S

Private Placement in 2019
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.

Versartis

Series D in 2013
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

DiObex

Series A in 2005
DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.

Coherus Biosciences

Series C in 2014
Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Coherus Biosciences was established in 2010 and is headquartered in Redwood City, California.

Ascenta Therapeutics

Series B in 2004
Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).

Taptu

Series A in 2007
Taptu is a social and media technology company. We build innovative platforms, tools and applications that enable highly personalized creation, curation, recommendation, search, discovery, management, consumption and sharing of content across all personal screen-based devices. Our flagship product is My Taptu, a social news aggregator currently available for the iPhone, iPhone Touch and Android mobile devices. Our other products include Taptu Touch Search and Wapedia, both available for apps on the iPhone and Android devices, and as a mobile web site for other mobile phones. Founded in 2007, Taptu is privately held and capitalized by leading investors, DFJ Esprit and Sofinnova.